Skip to main content
. 2022 Mar 3;10(3):303–313. doi: 10.1158/2326-6066.CIR-21-1083

Figure 1.

Figure 1. Multidimensional assessment of in-transit melanoma metastases treated with intralesional IL2. A, Study design. Multiple cutaneous in-transit metastases were excised from each melanoma patient, including at least one untreated (UT) and one IL2-injected lesion. Treatment response for IL2-injected lesions was classified as complete response or non-CR. B, Allocation of consecutive tumor tissue sections for molecular analyses. C, Summary of molecular analyses completed for each lesion. “Nonresponder” refers to all non-/mixed responder patients.

Multidimensional assessment of in-transit melanoma metastases treated with intralesional IL2. A, Study design. Multiple cutaneous in-transit metastases were excised from each melanoma patient, including at least one untreated (UT) and one IL2-injected lesion. Treatment response for IL2-injected lesions was classified as complete response or non-CR. B, Allocation of consecutive tumor tissue sections for molecular analyses. C, Summary of molecular analyses completed for each lesion. “Nonresponder” refers to all non-/mixed responder patients.